Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
To assess preliminary safety and efficacy of ganaxolone as adjunctive therapy for the
treatment of primary seizure types in patients with genetically- or clinically-confirmed
TSC-related epilepsy through the end of the 12 week treatment period.